Crucell N.V. Revenue and Competitors
Estimated Revenue & Valuation
- Crucell N.V.'s estimated annual revenue is currently $19.2M per year.
- Crucell N.V.'s estimated revenue per employee is $155,000
Employee Data
- Crucell N.V. has 124 Employees.
- Crucell N.V. grew their employee count by -9% last year.
Crucell N.V.'s People
Name | Title | Email/Phone |
---|
Crucell N.V. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is Crucell N.V.?
Biotechnology; Pharmaceuticals
keywords:N/AN/A
Total Funding
124
Number of Employees
$19.2M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Crucell N.V. News
2022-04-19 - Global Tratamiento de la infección por H3N2 Mercado Análisis ...
AIMM Therapeutics BV, Aphios Corporation, Crucell NV, CSL Limited, Glide Pharmaceutical Technologies Limited, ILiAD Biotechnologies LLC,...
2022-04-17 - Influenza Virus Vaccine (H1N1) Market Size And Forecast | Butantan ...
... Biological Engineering Inc, Cantacuzino Institute Of Sera And Vaccines, Changchun Institute Of Biological Products And Crucell N.V..
2022-02-22 - Global HIV Vaccines Market Research Report to 2027 - Featuring AlphaVax, Crucell and Novartis Among Others - ResearchAndMarkets.com
Global HIV Vaccines Market Research Report to 2027 - Featuring AlphaVax, Crucell and Novartis Among Others - ResearchAndMarkets.com.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $31M | 124 | 10% | N/A |
#2 | $25.4M | 124 | 5% | N/A |
#3 | $30.1M | 124 | 0% | N/A |
#4 | $12.4M | 124 | 17% | N/A |
#5 | $40.1M | 124 | 16% | N/A |